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The diagnosis of ECL-omas is easy to perform. In patients with Zollinger-
Ellison syndrome (ZES), ECL-omas are almost always observed in the setting
ofmultiple endocrine neoplasia type I. In patients without ZES, the first step is
to discard non-gastrin-related sporadic ECL-omas whose prognosis is poor. By
contrast, prognosis ofECL-omas in patients with ZES or chronic atrophic gas-
tritis is good. Metastases are rare, and tumor-related deaths are exceptional. In
both conditions, ECL-omas measuring less than 1 cm should be treated by endo-
scopic polypectomy and survey. Treatment modalities (surgery, endoscopic
polypectomy) for larger tumors are still discussed. The impact of endoscopic
ultrasonography on the therapeutic decision has not yet been evaluated.
Considering the good prognosis of these tumors, aggressive surgery could be
limited to selectedpatients. Multicentric studies shouldbe undertaken todetermine
the best treatment modalities.
INTRODUCTION
In man, fundic, well-differentiated, carcinoid tumors mainly composed of ECL cells
(ECL-omas) are observed in clinical conditions associated with sustained chronic hyper-
gastrinemia, such as Zollinger-Ellison syndrome (ZES)d (type 1 ECL-omas) [1-4] and
chronic atrophic gastritis type A (CAG-A) (type 2 ECL-omas) [4-18], and also indepen-
dently from hypergastrinemia, where they are called sporadic ECL-omas (type 3 ECL-
omas) [4, 11, 19]. By contrast to the gastrin-related carcinoids, sporadic ECL-omas are
most often single, large and deeply invasive. Furthermore, patients with sporadic ECL-
omas often die from liver metastases. The main clinicopathological differences between
the three types ofECL-omas are summarized in Table 1 [4].
Owing to major differences in natural history and mortality between gastrin-related
ECL-omas and sporadic ECL-omas, treatment modalities vary markedly. In patients with
sporadic type 3 tumors, total gastrectomy with "en bloc" removal ofregional lymph nodes
is mandatory when unresectable liver metastases are not present and systemic therapy
(chemotherapy or other antitumoral therapies) when they are present [4, 8, 9, 16, 19]. In
patients with gastrin-related ECL-omas, the optimal management is not clearly estab-
lished. Therefore, this review will only concern management (i.e., diagnosis and treat-
ment) ofECL-omas encountered in patients with CAG-A and with ZES.
aTo whom all correspondence should be addressed: Dr G. Cadiot, Service d'Hepato-
Gastroenterologie, CHU Bichat-Claude Bernard, 46, rue Henri Huchard, 75877 Paris Cedex 18,
France. Tel.: 33-1-40-25-72-01. Fax: 33-1-40-25-87-83.
dAbbreviations: ZES, Zollinger-Ellison syndrome; CAG-A, chronic atrophic gastritis type A; MEN
1, multiple endocrine neoplasia type 1.
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DIAGNOSIS OF FUNDIC ECL-OMAS
The diagnosis ofECL-omas is easily performed by the histological analysis ofendo-
scopic biopsies of the polyps, as it will be discussed below. In patients with ZES, ECL-
omas mainly occur in patients with multiple endocrine neoplasia type 1 (MEN 1).
Therefore, performing a diagnosis of ECL-oma in ZES patient must lead to an extensive
search for MEN 1. In patients without ZES, the initial step is to formally discard sporadic
ECL-omas (i.e., those occurring in non-atrophic fundic mucosa) and also the poorly-dif-
ferentiated neuroendocrine carcinomas that are not considered as ECL-omas and adeno-
carcinomas. The first part of this section will focus on conditions favoring ECL-oma
development for both types of tumors.
Patients with the ZES
Conditionsfavoring ECL-oma development in the ZES. In patients with ZES, ECL-
omas are observed almost exclusively in the small subgroup of patients in whom ZES is
part ofMEN 1 [1, 2, 4, 20]. This subgroup represents about 20 percent ofthepatients with
ZES. In our published series of 48 patients with ZES in whom a histological analysis of
the fundic mucosa was performed, five had fundic argyrophil carcinoid tumors [1]. All
these patients had MEN 1 and none had the sporadic type ofthe disease. In this group, the
prevalence ofsuch tumors was very high (29.5 percent). In the recent series from the NIH
published as an abstract form, five (4 percent) among 116 consecutive patients with ZES
who underwent fundic biopsies had carcinoids [20]. All these tumors were observed in
patients with MEN 1, giving aprevalence of24percent in this group [20]. To ourknowledge,
fundic argyrophil carcinoid tumors have been observed in three patients with sporadic
ZES [21-23]. In the two published cases, carcinoids were single and microscopic [21, 22].
Both patients had severe disease with multiple distant metastases not related to the fundic
carcinoid tumors. Microcarcinoids were discovered incidentally on total gastrectomy
specimen [22] and on random biopsies [21]. Follow-up ofour published patient [21] con-
firmed that, two years later, MEN 1 was still absent. Another point demonstrating that in
our series ECL-omas are very frequent in patients with ZES and MEN 1 is given by the
very large incidence of new ECL-omas in a series of 21 patients with ZES (initially free
of ECL-omas) who were endoscopically followed under omeprazole therapy [24]. ECL-
omas developed in three (43 percent) among the seven patients with MEN 1 and in no
patients with sporadic ZES (Table 2). Carcinoids appeared after 29, 48 and 69 months of
follow-up. In the fourotherpatients with MEN 1 but without carcinoids, the median follow-
up was 34.5 months (range 19-56), and in the 14 patients with sporadic ZES, it was 34.5
months (range 4-79) [24].
In onepatient with ZES andMEN 1, it was shownthatthe twocopies ofthe MEN 1 gene
were inactivated [25]. Because MEN 1 gene is a tumor suppressor gene, these genetic
events probably explain the major impact of MEN 1 on ECL-oma development. This
probably alsoexplains whyECL-omas areoftenmultiple. To ourknowledge, fundic argyrophil
cell dysplasiahas notbeen observed in patients with sporadic ZES, except in ourpatient with
carcinoids in whom dysplasia was noted before the diagnosis of carcinoid has been per-
formed [1, 21, 26]. The level ofECL cell density can be as high in patients with sporadic
ZES as inthosewithZES andMEN 1 [1,27]. Therefore, itis mostlikelythatthereis nodirect
histogenetic link between fundic ECL cell hyperplasia and dysplasia/carcinoid [25, 26].
Clinical and endoscopical diagnosis ofECL-omas: To our knowledge, fundic ECL-
omas do not give specific symptoms in patients with ZES. These tumors are discovered
incidentally during endoscopy showing polypoid formations or diagnosed on random
biopsies ofanon-polypoid mucosa (microcarcinoids) or at examination oftotal gastrectomy
specimen [1-3, 22, 28].
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Table 2. Development offundic argyrophil dysplasia and carcinoids in 21 ZES patients treat-
ed with omeprazole during a median period ofthree years (from Ref. [24]).
Fundic argyrophil cell dysplasiaa Fundic argyrophil carcinoidsa
At time offirst At time oflast At time of first At time oflast
Patients biopsies (n) biopsies (n) biopsies (n) biopsies (n)
Sporadic (n=14) 0 0 0 0
MEN I (n=7) lb +1 0 +3
a According to Solcia et al. [7].
b In a fundic polyp. The patient further developed carcinoids.
In our series, the diagnosis ofECL-omas was always established afterthatofZES [1].
No precise data in the literature have specifically concerned the conditions of carcinoid
diagnosis in ZES. Because carcinoids have been found at examination of surgically-
resected stomach specimen before the availability ofpotent antisecretory drugs or shortly
after the initiation of such therapy, it is probable that ECL-omas can develop early in the
course ofZES [1, 2].
Except MEN 1, no clinical condition seems to be associated with an increased risk in
ECL-omas (Table 3) [1]. Sex-ratio of patients with ECL-omas is about 1 [1, 4]. Age at
diagnosis is variable, as is duration ofZES [1]. Gastrin levels are high (up to 140 times
the upper limit ofnormal), but one patient had low serum gastrin levels (twice this limit)
[1]. Type and duration ofantisecretory treatments seem to have no influence [1]. The only
condition in which microscopic ECL-omas could be suspected is the presence of fundic
argyrophil cell dysplasia on random biopsies [21, 24].
When macroscopic, ECL-omas are usually small (< 1 or 2 cm) and multiple (Tables
1 and 3) [1, 4]. At time of initial diagnosis, we observed a predominant localization just
above the antro-fundic transitional zone [1]. Typically, tumors are umbilicated.
To our knowledge, no seric marker that could suggest the presence ofECL-omas has
been tested in ZES. ECL-omas secrete chromogranin A [29], histamine [30] and alpha
HCG [31]. Syversen et al. have suggested that serumchromograninAlevels inZES reflect
the ECL cell mass [29]. However, this marker has not been tested as a diagnostic tool of
ECL-omas in ZES patients. Increased levels of alpha HCG in ZES seem to be related to
the gastrinoma mass [32]. Therefore, it is probable that this marker is not useful for sus-
pecting ECL-omas.
Patients with CAG-A
In patients without ZES, thefirst step is to affirm thatthe patienthas CAG-A, in order
to discard sporadic ECL-oma. The minimal investigations to be performed are: a) multiple
biopsies (at least four) in the non-tumoral fundic mucosa (mucosa must be atrophic, argy-
rophil cell hyperplasia is most often present) and biopsies ofany mucosal abnormality in
order to discard otherassociated lesions (early adenocarcinoma, etc.); b) pentagastrin-acid
output determination (achlorhydria must be present); and c) serum gastrin level measure-
ment (hypergastrinemia is almost always present) and antral biopsies (standard staining,
G-cell staining). When CAG-A is diagnosed, a search for pernicious anemia should be
undertaken.
Conditions favoring ECL-oma development: In patients with CAG-A, there are no
predictive signs ofECL-oma development. Serum gastrin levels are very high in CAG-A
patients with ECL-omas and often higher, but not always, than in CAG-A patients with
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Table 3. Characteristics ofsix personal published cases ofZES patients withfundic argyrophil
carcinoid tumors at time oftheir detection (modified from Refs. [1] and [21]).
Antisecretory Serum
Sex-age Men 1 ZES duration treatment gastrin Fundic
(yr) (+/-) (yr) (duration) (pg/ml) lesions
F-55 + 12 Anti-H2 (5 yr) 14000 100 polypsa
M-36 + 15 Anti-H2 (5.5 yr), 4193 Several polypsb
then Om (3.5 yr)
M-36 + 2 Anti-H2 (2 yr) 2390 Microcarcinoidsc
F-49 + 28 Anti-H2 (7.5 yr), 4718 12 polypsd
then Om + SMS (4 yr)
M-52 + 8 Anti-H2 + P (6.5 yr), 229 1 polype
then Om (7.5 yr)
F-69f - 12 Anti-H2 (3 mo), 520 1 microcarcinoid
then Om (1 yr) (0.65 mm)
Normal serum gastrin level: 100 pg/ml.
Anti-H2: H2-receptor antagonists; Om: omeprazole; P: pirenzepine; SMS: octreotide.
a Total gastrectomy three months later; maximal carcinoid size: 1 cm; 1 lymph node: Grimelus-
positive and gastrin-negative.
b Total gastrectomy four years later (serum gastrin: 13883 pg/ml), hundreds ofECLomas,
maximal carcinoid size: 4 cm.
c Discovered fortuitously on gastrectomy specimen performed for non-compliance to treatment.
d One fundic polyp (corresponding to argyrophil cell dysplasia) was removed at the end of
anti-H2 treatment (serum gastrin: 1063 pg/ml).
e One year later: 3-4 polyps (serum gastrin: 500 pg/ml).
fThis patient has bone and liver metastases from gastrinoma.
focal nodular hyperplasia without ECL-omas, with overlapping values between patients
with and without carcinoids [5, 33, 34]. In a literature review, Cattan noted that, among
68 cases, 10 hadgastrin levels between 4000 and 11000pg/ml, 13 between 2000 and 4000
pg/ml, 18 between 1000 and 2000 pg/ml and 27 below 1000 pg/ml [35]. There we'e at
least eight cases with gastrin levels below 500 pg/ml (i.e., 2.5-4 times the upper limit of
normality that varies from 120 to 200 pg/ml in the different series [35]).
Age ofpatients presenting withECL-omas is variable (from 15 to 88 years), but mean
age is elevated (63 years) (Table 1) [4]. Sjoblom et al. have suggested that duration ofper-
nicious anemia is longer inpatients with ECL-omas than in patients without these tumors,
all tumors being found in patients with more than five years disease duration [33].
However, evaluating the duration ofpernicious anemia is difficult.
ECL-omas are more often observed in females than in males (Table 1) [4]. This might
reflect the predominance of females among patients with pernicious anemia [6] or the
influence of female sex on ECL cell proliferation. In patients with CAG-A, the influence
ofpernicious anemia on the degree of argyrophil cell hyperplasia is debated [6, 36]. In a
literature review, 47 percent of ECL-omas (81 among 174 cases of CAG-A) occurred in
patients with pernicious anemia [19]; therefore, it is not known whetherpernicious anemia
increases the risk ofECL-oma development in patients with CAG-A.
ECL-omas are often associated with an important linear or nodular ECL cell hyper-
plasia in the non-tumoral mucosa; however, the density ofargyrophil cells was not signifi-
cantly higher in patients with ECL-omas than in patients with nodular hyperplasia but
withoutECL-omas [12, 34]. In apatientwithout macroscopic ECL-omaandwithargyrophil
cell dysplasia, multiple fundic biopsies should be repeated to recognize microcarcinoids.
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Diagnosis ofECL-omas inpatients with CAG-A: Thesetumors aregenerally discovered
incidentally because of non-specific symptoms (dyspepsia, nausea, pain, etc.) or on
screening endoscopy [5, 6, 8, 10, 13, 14, 16, 18]. They never give rise to carcinoid syn-
drome nor to atypical carcinoid syndrome. Anemia due to iron deficiency or hemorrhage
has been described [5, 14]. An old series showed that carcinoids can be detected before,
at time, or after diagnosis of CAG-A [10]. However, recent series with systematic
endoscopy showed that the rate ofdetection ofcarcinoids is higher at the first endoscopy
(1.25 percent to 7.8 percent) and lower (0 percent to 3.6 percent) during the follow-up of
those patients without carcinoids at the first endoscopy [6, 13, 37-40]. Roucayrol and
Cattan also showed that no carcinoid developed in 19 patients followed for a mean time
of 69 months (11-170 months) [41]. This suggests, as for other preneoplastic conditions,
such as Barret's esophagus or liver cirrhosis, that the first screening examination is the
most important in terms ofdetection rate.
Endoscopical aspects of ECL-omas in patients with CAG-A are similar to those of
ECL-omas noted in patients with ZES, although they are less often multiple and more
often ofsmall size (Table 1). Most often, polypoid lesions in the stomach ofpatients with
pernicious anemiado notcorrespond to carcinoids. In a series of80 patients, 18 had antral
and/or fundic polyps [13]. Among the 16 patients with available histological analysis of
the polyps, eight (50 percent) had hyperplastic polyps, and one patient only had multiple
carcinoids [13]. The polyps in the other patients corresponded to hyperplasia and severe
dysplasia (n = 1), granulation tissue (n = 1), mucosa with atrophy (n = 3), mild dysplasia
(n = 1) and inflammation (n = 1) [13]. In another series, 60 among 123 patients (49 per-
cent) had one or several polypoid lesions [37]. They corresponded to benign hyperplastic
and/or inflammatory gastric polyps (mostly in the body/corpus) in 52 patients (87 per-
cent), to carcinoids in five, to adenoma (n = 1) and to early adenocarcinoma (n = 2) [37].
Therefore, all polyps, or the highest possible number, should be resected for full histo-
logical analysis, mainly in order to diagnose adenocarcinoma.
The serum or plasma levels of the following peptides were not increased in patients
with ECL-omas: calcitonin, parathyroid hormone, glucagon, motilin and somatostatin [6].
To our knowledge, serum chromogranin A has not been measured in these patients.
HISTOLOGICAL DIAGNOSIS OF ECL-OMAS IN
PATIENTS WITH ZES OR CAG-A
ECL-omas observed in patients with ZES or with CAG-Ahave similarmorphological
aspects that have been well described by several authors [1, 2, 6, 7, 11, 19]. Tumors are
well-differentiated, argyrophil, and immunoreactive for chromogranin A, synaptophysin
and neuron specific enolase. Immunoreactivity for peptides is generally negative or only
scattered cells are positive. No other fundic carcinoid tumors than ECL-omas have these
morphological characteristics. Ifpossible, and ifit is necessary, the conclusive diagnosis of
ECLcell tumoris doneby the ultrastructural examination ofthepolyps that shows that most
tumoral cells correspond to ECL cells. Tumoral ECL cells are well recognized by their
granules, either typical, containing vesicular electron dense granules, or atypical, with
non-vesicular granules displaying acoarsely granular structure. Othertumoral cell types can
be present (EC, X, P/D1, Alike). Routine detection ofhistamine in the tumors is difflcult.
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TREATMENT OF ECL-OMAS
Treatment of ECL-omas depends on their natural history and on the morbidity and
mortality direcdlyrelated tothetumors themselves andtheappliedtherapies. Treatmentmodal-
ities are largely debated in both conditions, except for tumors measuring less than 1 cm.
Patients with ZES
Although very few ECL-omas have been published in patients with ZES, the benign
evolution of these tumors seems to be the rule [4, 19]. Metastases to local lymph nodes
have been noted in three of 10 cases in the largest series and distant metastases in one of
these three patients [4]. In a compilation of cases from literature review by the same
authors, only three among 27 cases had lymph node metastases [19]. One patient with
ECL-omas and liver metastases died from its metastases (Table 1) [4]. To our knowledge,
this is the only case with ECL-oma-related mortality. It must be emphasized that the origin
ofmetastases is very difficult to ascertain inthesepatients. Endocrine lymphnode metastases
are very frequent in patients with ZES and MEN 1, and liver metastases develop in about
10 percent ofthem [42, 43]. The only way to discriminate metastases ofECL-omas from
metastases ofgastrinomas or ofother types ofendocrine tumors is to perform ultrastructural
analysis or in situ hybridization of the resected lymph nodes or liver metastases when
immunohistochemistry using peptide antibodies is negative [44]. For example, negative
immunohistochemistry using gastrin antibodies does notrule outthediagnosis ofmetastases
from gastrinoma. To our knowledge, this has not been performed in the above-mentioned
cases. Therefore, all cases with metastases must be cautiously discussed. Two of our
patients with ZES-MEN 1 and ECL-omas further developed distant metastases (unpub-
lished data), but there is no formal argument to attribute metastases to ECL-omas. One
developed gastrin-immunoreactive liver metastases five years after total gastrectomy for
multiple ECL-omas, and the other developedlivermetastases not immunoreactive to gastrin
antibodies and also multiple pulmonary nodules (not biopsied) two years after the diag-
nosis of one small ECL-oma. Another patient already had multiple pulmonary nodules
several years before the diagnosis ofECL-omas was done.
Data concerning the evolution ofsize and number ofECL-omas during follow-up are
sparse. In our experience, carcinoids slowly increased in number in the three patients not
treated initially by total gastrectomy. Especially, one patient developed hundreds of
tumors, which size reached 3-4 cm (Table 3) [1]. It must be also noted that the evolution
in number and size is extremely difficult to assess endoscopically in those patients with
enlarged gastric folds.
Because the number ofpublished patients is very small, metastases are very rare and
there are no clear data on tumor evolution, it is currently not possible to evaluate the rela-
tionship between any morphological characteristic, especially the depth ofgastric involve-
ment, and prognosis that would help therapeutic decisions. Therefore, it is not known
whether endoscopic ultrasonography, which is accurate for demonstrating submucosal or
deeper gastric wall involvement or lymph node involvement [45], has any interest for
deciding treatment modality.
Treatment indications for ECL-omas developing in patients with ZES are largely
unknown. Treatment modalities include total gastrectomy, surgical resection of the
tumors, endoscopic polypectomy, somatostatin analogues and survey. Most patients with
ZES and MEN 1 have multiple endocrine tumors (gastrinomas and other endocrine
types) in the duodenal wall and pancreas. Therefore, patients with ZES and MEN 1 are
almost never cured by surgery [46, 47], if performed, and the fundic mucosa of these
patients will be submitted to gastrin stimulation for life. Furthermore, ECL-omas are
generally multicentric, and some have tendency to increase in number. Therefore, total
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gastrectomy might be the best theoretical way to eliminate the tumors. The prognosis of
ZES and MEN
1 essentially depends on the presence of liver metastases [42, 46]. The
prognosis of patients without liver metastases at time of ZES diagnosis is excellent [42],
92 percent at 10 years in our recent experience [43]. Total gastrectomy could induce a
higher morbidity and mortality than ECL-omas themselves and, furthermore, would limit
the possibility of further duodenal or pancreatic resection, which might be necessary, for
example, ifinsulinoma or a large tumor develops. Especially, duodenopancreatectomy is
contraindicated in patients with previous gastrectomy. In several patients, including two
ofour series, total gastrectomy was performed because ofhundreds ofECL-omas [1, 28].
In the first case, the decision to perform total gastrectomy was taken because no specific
guidelines were available for accurate treatment at that time [28]. In the second case, the
decision to perform total gastrectomy was taken because carcinoids were continuously
increasing in number and size, and there was no remaining normal fundic mucosa.
However, it is not known whether this attitude improved survival. Especially, as already
mentioned in the latter patient in whom a non-curative left pancreatectomy had been per-
formed earlier, liver metastases of gastrinomas developed five years later. The decision
to perform total gastrectomy must take into account the other prognostic factors related
to ZES and MEN 1. When total gastrectomy is decided, the surgeon should also resect
duodenal gastrinomas and enucleate pancreatic tumors, if this does not significantly
increase morbidity and mortality.
With the exception of the very rare patients with very large tumors (up to 10 cm), as
described by Rindi et al. [4], or perhaps with tumors that extend beneath submucosa at
endoscopic ultrasonography examination, single or small multiple ECL-omas are proba-
bly at best treated by endoscopic polypectomy followed by regular endoscopic survey.
Recent data in animals and in patients with ZES or CAG-A suggest that somatostatin
analogues may have antiproliferative properties on fundic endocrine cells and ECL cells
[48-54]. ECL cells and ECL-omas bear somatostatin receptors [55, 56]. ECL-omas can be
visualized using Octreoscan scintigraphy [57]. In our unpublished experience, the fundic
carcinoid uptake is often diffuse and not as high as for other endocrine tumors. The anti-
tumoral properties of somatostatin analogues on ECL-omas in ZES has not been estab-
lished [57]. In one patient, ECL-omas occurred and developed despite octreotide therapy [1].
Therefore, at the moment, it cannot be recommended to use somatostatin analogues with
the only aim to treat ECL-omas. Similarly, somatostatin analogues have not been tested in
the intention to reduce recurrence after endoscopic or surgical resection of ECL-omas.
Finally, there are no definite modalities for surveying the fundic mucosa of patients
with ZES. In our department, endoscopy is performed yearly in all patients with the ZES
(sporadic and MEN 1) in particular for ECL-omas detection. At each endoscopy, four to
five fundic biopsies are done systematically. Grimelius staining is used to visualize argy-
rophil cells. In patients with ECL-omas, the survey is similar.
Treatment ofECL-omas in patients with CAG-A
More data exist about ECL-omas treatment in patients with CAG-A. Local lymph
node involvement should be screened by endoscopic ultrasonography and distant metas-
tases by CT scan or magnetic resonance imaging. Octreoscan scintigraphy has not yet
been evaluated in this peculiar situation. Lymph node involvement and liver metastases
are very rare, 2 percent in the largest series, without any ECL-oma-related death (Table 1)
[4]. From a literature review, it has been shown that lymph node metastases were present
in 17 (7.6 percent) among 224 patients and distant metastases in four (1.8 percent) patients
[19]. In another literature review, lymph nodes were present in 3.2 percent of 156 patients
and distant metastases in 1.3 percent [15]. Metastatic rates were higher in the previous
series published by Carney et al.: eight (13 percent) patients had lymph node metastases
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and three (5 percent) had liver metastases, with one (1.6 percent) related-death [10], but
ulterior series showed that the related death was nil [4, 11, 15, 16, 37-40]. Life expectancy
in patients with ECL-omas has been shown to be similar to that ofan age-corrected control
population [14, 15]. It must be emphasized that due to the relatively old age of these
patients, mortality due to other causes than ECL-omas is very high during follow-up, 14
percent to 27 percent [4, 10, 14, 15, 37].
Although precise data are lacking, it is generally accepted that tumors measuring less
than 1 cm do not metastasize, and tumors measuring more than 1 cm are at risk to give
metastases [8, 27, 35, 58-60]. The major therapeutic problem is to define, among patients
with tumors measuring more than 1 cm, the rare patients who are at risk for development of
lymph node or liver metastases (i.e., to define the patients in whom the surgical resection
ofthe tumors is mandatory and those who can be treated endoscopically). Data concerning
the relationship between gastric wall depth involvement and metastases are sparse. In two
series containing four patients with tumors measuring 1.0, 1.0, 1.2 and 1.5 cm, respectively,
and metastases, no data concerning wall infiltration were given [4, 8]. Infiltration of the
muscularis mucosa was noted in two patients with 2 cm- and 3 cm-carcinoids and metas-
tases [59]. Among five cases with carcinoids measuring more than 1 cm (up to 1.7 cm),
three patients had tumors that infiltrated into the muscularis mucosa, with invasion ofthe
lymph vessels in two, but none had metastases [15]. By contrast, in this series, the maximal
infiltration depth of 83 tumors measuring less than 1 cm was limited to the submucosa
[15]. In a series of 14 patients, the only patient with lymph node metastases had serosal
involvement and multiple carcinoids (one reaching 2 cm), none of the other 13 patients
had carcinoids measuring more than 1 cm [5, 61]. The maximal depth involvement was
limited to the submucosa in five studied patients [5, 61].
Spontaneous regression of ECL-omas measuring more than 1 cm (up to 1.5 cm) has
been observed [62]. Antrectomy, leading to normalization of serum gastrin levels, also
induced total or partial regression ofECL-omas [8, 59, 60]. Four studied patients had car-
cinoids measuring 1.2 cm or more (up to 3 cm) [8, 59, 60], and three ofthem had lymph
node or liver metastases that were also resected [8, 59]. Finally, after surgical resection
without antrectomy or after endoscopic polypectomy, the recurrence rate seems to be low
[8, 10, 35, 37, 39, 58].
Treatment protocols vary [4, 8, 15, 35, 58, 63]. The clinical condition ofthe patients
must be considered, because many are old and will die forother reasons. All authors agree
to treat endoscopically tumors measuring less than 1 cm. Owing to the general benign
evolution, surgery could be limited to patients with tumors larger than 1 cm in whom
endoscopic ultrasonography shows infiltration of the muscularis mucosa or lymph node
involvement. To our knowledge, only a few patients with fundic carcinoids have been
studied by endoscopic ultrasonography [45]. Its accuracy for determining gastric wall
depth involvement and local lymph node involvement is good [45]. Whether local surgical
excision or antrectomy with surgical excision of the tumors are the best surgical treat-
ments is not clearly established. The choice between these two modalities should rely on
the number and size ofthe tumors. Indication for total gastrectomy is probably very rare.
Concerning survey, we propose: a) to always perform a first endoscopy with biopsies
in all patients with CAG-A whatever the age; b) to stop survey in patients older than 70
years of age, unless adenoma, adenocarcinoma or severe dysplasia are present; c) in
patients under 70 years, to survey (endoscopy with multiple biopsies) every three years
those without ECL-omas and yearly those with ECL-omas.
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CONCLUSIONS
After sporadic ECL-omas or other types ofmalignant tumors have been formally dis-
carded, tumors less than 1 cm should be treated endoscopically, in both patients with ZES
orCAG-A. Forbigger tumors, therapeutic decisions should atbestbe discussedpatient by
patient. The various parameters that should be taken into account are: the clinical condition
ofthe patient, the number and size ofthe tumors, the results ofendoscopic ultrasonography,
especially gastric wall depth and lymph node involvement, and also the results ofthe pre-
vious treatments. Treatment-related morbidity and mortality should be less than that ofthe
ECL-omas themselves. Multicentric studies, including endoscopic ultrasonography, aiming
to evaluate the different therapeutic modalities should be undertaken.
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